Hangzhou Tigermed Consulting
Hangzhou Tigermed Consulting Co Ltd is a contract research organization headquartered in Hangzhou, China. The company delivers clinical trial management, medical writing, regulatory affairs, biostatistics, and data management services. Its operational offerings support pharmaceutical and medical device companies through phase one through phase four clinical development programs. Revenue is primarily generated through fee-for-service clinical trial management contracts and research laboratory services. The business serves pharmaceutical firms, biotechnology companies, and medical technology enterprises across Asia, North America, and Europe. Hangzhou Tigermed Consulting Co Ltd is dual-listed on the Shenzhen Stock Exchange and Hong Kong Stock Exchange.
9 of the funds FundTelligence covers report a position in Hangzhou Tigermed Consulting.
- Legal name
- Hangzhou Tigermed Consulting Co Ltd
- Sector
- Health Care
- Country
- China
- Funds holding it
- 9
Funds holding Hangzhou Tigermed Consulting
- Nordea Chinese Equity Fund — Nordea Funds · 0.71 % (full portfolio disclosed, September 2026)
- Nordea China — Nordea Funds · 0.7 % (full portfolio disclosed, September 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.06 % (full portfolio disclosed, October 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.05 % (full portfolio disclosed, September 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, September 2026)
- Mercer Passive Emerging Markets Equity Fund — Mercer · 0.01 % (full portfolio disclosed, December 2025)
- KLP AksjeFremvoksende Markeder Indeks — KLP · 0.0 % (full portfolio disclosed, June 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.0 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 9 funds holding it.